ArticleAntimicrobial agents and chemotherapy1999
A novel injectable water-soluble amphotericin B-arabinogalactan conjugate.
Article in Antimicrobial agents and chemotherapy, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 87 citations in OpenAlex.
- A Comprehensive Review on Engineering Release at the Molecular Level: Role of Functional Groups in Polysaccharide-Based Drug Delivery.Materials (Basel, Switzerland) · 2026Review
- Water-Soluble Nystatin and Derivative.ACS medicinal chemistry letters · 2022Article
- A Functional Wound Dressing as a Potential Treatment for Cutaneous Leishmaniasis.Pharmaceutics · 2019Article
- Characterization of a Polyethylene Glycol-Amphotericin B Conjugate Loaded with Free AMB for Improved Antifungal Efficacy.PloS one · 2016Article
- Novel Nystatin A₁ derivatives exhibiting low host cell toxicity and antifungal activity in an in vitro model of oral candidosis.Medical microbiology and immunology · 2014Article
- In vitro efficacy of corifungin against Acanthamoeba castellanii trophozoites and cysts.Antimicrobial agents and chemotherapy · 2014Article
- Biosynthesis and pathway engineering of antifungal polyene macrolides in actinomycetes.Journal of industrial microbiology & biotechnology · 2013Review
- Toxicity mechanisms of amphotericin B and its neutralization by conjugation with arabinogalactan.Antimicrobial agents and chemotherapy · 2012Article
- Corifungin, a new drug lead against Naegleria, identified from a high-throughput screen.Antimicrobial agents and chemotherapy · 2012Article
- Injectable in situ cross-linking hydrogels for local antifungal therapy.Biomaterials · 2010Article
- The in vitro characterization of polyene glycosyltransferases AmphDI and NysDI.Chembiochem : a European journal of chemical biology · 2008Article
- Amphotericin B-gum arabic conjugates: synthesis, toxicity, bioavailability, and activities against Leishmania and fungi.Pharmaceutical research · 2007Article
- Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis.Antimicrobial agents and chemotherapy · 2004Article
- Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres.Antimicrobial agents and chemotherapy · 2004Article
- Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives.Antimicrobial agents and chemotherapy · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New, stable, highly water-soluble, nontoxic polysaccharide conjugates of amphotericin B (AmB) are described. AmB was conjugated by a Schiff-base reaction with oxidized arabinogalactan (AG). AG is a highly branched natural polysaccharide with unusual water solubility (70% in water). A high yield of active AmB was obtained with the conjugates which were similarly highly water soluble and which could be appropriately formulated for injection. They showed comparable MICs for Candida albicans and Cryptococcus neoformans (MICs, 0.1 to 0.2 microg/ml). The reduced AmB conjugate, which was synthesized at pH 11 for 48 h at 37 degrees C, was nonhemolytic and was much safer than conventional micellar AmB-deoxycholate. It was the least toxic AmB-AG conjugate among those tested with mice (maximal tolerated dose, 50 mg/kg of body weight), and histopathology indicated no damage to the liver or kidneys. This conjugate, similarly to the liposomal formulation (AmBisome), was more effective than AmB-deoxycholate in prolonging survival. It was more effective than both the liposomal and the deoxycholate formulations in eradicating yeast cells from target organs. The overall results suggest that after further development of the AmB-AG conjugate, it may be a potent agent in the treatment of fungal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.